Guru Infla-650 Review

Infla-650 is a capsule product sold by GURU Inc. (Georgia, USA) as an "herbal dietary supplement" for joint pain, muscle discomfort and inflammation. Retailers and affiliate sites describe it as an Ayurvedic-style herbal blend. The recalled lot (IN-032) came in 700 mg capsules. The labeled ingredients include ashwagandha and fenugreek, and some retail pages also list turmeric (curcumin) and boswellia. Those pages say turmeric reduces joint pain and swelling, and that boswellia supports joint function. The label's mechanism is the traditional herbal one. Curcumin and boswellic acids are reported to dampen inflammatory signaling, including NF-κB, COX-2 and 5-LOX pathways. Ashwagandha and fenugreek are positioned as adaptogenic and supportive herbs. Sellers claim this "targets pathways involved in inflammation" and supports recovery of joints and muscles. This is not what the product actually does, and it should not be bought or used. In June 2024, the FDA advised consumers not to purchase or use Infla-650. FDA laboratory analysis confirmed that Infla-650 contains a med, diclofenac and phenylbutazone, and none of these are listed on the label. On July 16, 2024, Guru Inc. issued a recall of one lot of Infla-650 Herbal Dietary Capsules for this reason. The relief users feel is therefore most plausibly pharmacological, not herbal. - **Diclofenac** is a med. It inhibits COX-1 and COX-2 enzymes, which lowers prostaglandin synthesis, and that reduces pain, swelling and inflammation. - **Phenylbutazone** is an older a med. It is now used mainly in veterinary medicine, and it carries risks of serious blood disorders such as agranulocytosis and aplastic anemia. - **a med** acts centrally to relieve pain and fever. Combined with the other drugs, it risks unintentional overdose and liver injury. The FDA states that use of the product poses a serious threat to consumers. The risks include a med overdose. Diclofenac and phenylbutazone also carry the usual a med risks of GI bleeding, kidney injury, and heart attack and stroke. Hidden a med-like or a med effects can also cause problems when a person stops taking them suddenly. The FDA also treats the product as an unapproved new drug whose safety and efficacy have not been established. People on meds, people with kidney, liver or heart disease, and pregnant people are at particular risk. Anyone who has this product should stop using it and talk to a healthcare provider. Adverse events can be reported to FDA MedWatch.